| Value | ₹800.0 Cr |
|---|---|
| Execution period | 3 years (maturity 05 November 2028) |
BSE filing, NSE: JUBLPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Jubilant Pharmova Ltd: key numbers
- Share price
- ₹947.05
- Market cap
- ₹15,085 Cr
- Revenue (annual)
- ₹8,280 Cr
- Net profit (annual)
- ₹398.5 Cr
- P/E (TTM)
- 42.8×Sector 42.0×
- Promoter holding
- 47.68%+0.00% QoQ
- FII holding
- 15.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jubilant Pharmova Ltd
All →Jubilant Pharmova Board Meeting Date
Jubilant Pharmova has scheduled a board meeting for November 13, 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. The filing is a Regulation 29 advance intimation only.
Jubilant Pharmova Annual General Meeting
Jubilant Pharmova Ltd has issued a Postal Ballot Notice seeking shareholder approval for the private placement issuance of Non-Convertible Debentures.
Jubilant Pharmova Credit Rating
Jubilant Pharmova received a credit rating of IND AA+/Stable from India Ratings and Research for its proposed Non-Convertible Debentures worth ₹1,400 Crore.
- Value
- ₹1,400 Cr
Jubilant Pharmova Other Announcement
Jubilant Pharmova Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Jubilant Pharmova Credit Rating
Jubilant Pharmova received an [ICRA]AA+ (Stable) rating from ICRA for its proposed non-convertible debentures. This confirms the credit assessment for the upcoming debt instrument.
Jubilant Pharmova Debt & Borrowing: ₹800 Cr
Jubilant Pharmova board approved NCD issuance up to ₹800 crore on private placement basis. Postal ballot also sought for NCD authorization up to ₹2,500 crore.
- Value
- ₹800.0 Cr
- Execution
- Upto five years from the Deemed Date of Allotment
Other debt & borrowing announcements
All →Persistent Systems Debt & Borrowing: ₹600 Cr
Persistent Systems allotted 12,000 commercial papers worth INR 6 billion (₹600 Crore) on November 5, 2026. The one-year CPs carry an 8.75% yield and mature on November 5, 2027.
- Value
- ₹600.0 Cr
- Execution
- 1 year: allotment November 5, 2026 to maturity November 5, 2027
Nimbus Projects Debt & Borrowing: ₹60 Cr
Nimbus Projects' board finalised terms for a Rs 60 Crore unsecured loan from associate Nimbus (India) Limited. The loan carries 12% interest for two years.
- Value
- ₹60.00 Cr
- Execution
- 2 years
Fusion CX Debt & Borrowing: ₹42.3 Cr
Fusion CX lent USD 4.5 million, about Rs.42.30 Crore, to its UK subsidiary for onward lending to its Canadian subsidiary. The loan carries 8.5% interest over five years.
- Value
- ₹42.30 Cr
- Execution
- 5 years
Motilal Oswal Financial Services Debt & Borrowing: ₹275 Cr
Motilal Oswal Financial Services confirmed timely payment of its commercial paper maturing November 5, 2026. The redemption amount was Rs. 275 Crore.
- Value
- ₹275.0 Cr
Span Divergent Debt & Borrowing: ₹0.68 Cr
Span Divergent increased its HDFC Bank corporate guarantee for subsidiary Dryfruit Factory LLP by ₹0.68 Crore. Total guarantee now ₹5.68 Crore; no immediate financial impact.
- Value
- ₹0.68 Cr
Newmalayalam Steel Debt & Borrowing: ₹10 Cr
Newmalayalam Steel approved a ₹10 Crore corporate guarantee to HDFC Bank for subsidiary Prime NMS. It is a contingent liability with no immediate financial impact.
- Value
- ₹10.00 Cr